- Open Access
Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes
© Mbawuike et al. 2007
- Received: 07 February 2007
- Accepted: 27 June 2007
- Published: 27 June 2007
MHC class I-restricted CD8+ cytotoxic T lymphocytes (CTL) are thought to play a major role in clearing virus and promoting recovery from influenza infection and disease. This has been demonstrated for clearance of influenza virus from the lungs of infected mice. However, human influenza infection is primarily a respiratory mucosal infection involving the nasopharynx and tracheobronchial tree. The role of CD8+ CTL directed toward the influenza nucleoprotein (NP) in defense against influenza virus infection at the respiratory mucosa was evaluated in two separate adoptive transfer experiments.
Influenza nucleoprotein (NP)-specific CD8+ CTL were generated from splenocytes obtained from Balb/c mice previously primed with influenza A/Taiwan/1/86 (H1N1) infection or with influenza A/PR/8/34 (H1N1)-derived NP plasmid DNA vaccine followed by infection with A/Hong Kong/68 (H3N2) virus. After in vitro expansion by exposure to an influenza NP-vaccinia recombinant, highly purified CD8+ T cells exhibited significant lysis in vitro of P815 target cells infected with A/Hong Kong/68 (H3N2) virus while the CD8- fraction (CD4+ T cells, B cells and macrophages) had no CTL activity. Purified CD8+ and CD8- T cells (1 × 107) were injected intravenously or interperitoneally into naive mice four hours prior to intranasal challenge with A/HK/68 (H3N2) virus.
The adoptively transferred NP-vaccinia-induced CD8+ T cells caused significant reduction of virus titers in both the lungs and nasal passages when compared to CD8- cells. Neither CD8+ nor CD8- T cells from cultures stimulated with HIV gp120-vaccinia recombinant reduced virus titers.
The present data demonstrate that influenza NP-specific CD8+ CTL can play a direct role in clearance of influenza virus from the upper respiratory mucosal surfaces.
- Influenza Virus
- Influenza Virus Infection
- Virus Challenge
- Respiratory Mucosa
Studies in mice have shown definitively that MHC class I-restricted CD8+ CTL can promote recovery from pneumonia caused by an influenza virus infection [1, 2]. Proof was provided using adoptive transfer of CD8+ T cells and clones [3, 4, 1], in vivo depletion of CD8+ T cells using monoclonal antibodies from mice previously infected with influenza virus [5, 6] and transgenic CD8+ T cell knockout mice . CD8+ CTL mediated clearance of lung virus infection, reduced pneumonia severity and prevented mortality from the influenza virus infection.
Despite availability of data for mice, a beneficial role for CTL activity in promoting clearance of influenza virus infection in human influenza cannot be assumed because influenza in humans is primarily an infection of the mucosal surface of the respiratory tract; pneumonia can occur but this is uncommon . Thus, for CTLs to be of value for human influenza, they must mediate control of virus infection of respiratory tract epithelial cells. In this regard, it has been suggested that CTLs in the circulation or submucosal sites cannot cross the basement membrane of the mucosal surface; this should be necessary to exert an effect . Studies by McMichael and coworkers demonstrated a correlation between human HLA-restricted CTL activity and reduced viral shedding from the nasopharynx of humans; however a contribution from antibody could not be excluded .
CD8+ CTL for influenza virus infection are directed predominantly toward antigens on the nucleoprotein (NP) [11–14]. Antibody to NP has clearly been shown to have no role in prevention or recovery from infection [15, 16] so a beneficial immune response directed specifically toward the NP would be a cell mediated immune response; antibodies that could contribute to the control of influenza are directed toward the hemagglutinin and neuraminidase surface proteins  or the M2 protein . The objective of the present study was to define the role of CD8+ CTL directed toward the NP protein in defense against influenza virus infection of the respiratory mucosa.
Eight- to twelve- week old Balb/c (H-2d) mice were purchased from Charles River Laboratories under a contractual arrangement with the National Institute on Aging and were housed in specific pathogen-free-certified rooms in cages covered with barrier filters and with sentinel cages to monitor infections.
Virulent challenge pools of mouse-adapted influenza viruses A/Hong Kong/1/68 (A/H3N2) and A/Taiwan/1/86 (A/H1N1) viruses were prepared by serially passaging each virus in mice as described previously [18–20]. The NP of A/HK/68 and A/Taiwan/1/86 viruses are antigenically similar to each other and to A/PR/8/34 (H1N1) virus NP while the HA and NA surface glycoproteins of A/HK/68 and A/Taiwan/86 are antigenically distinct. A mouse fifty percent lethal dose (MID50) following administration by small particle aerosol (SPA) was determined for each virus as described previously [18–20]. A mouse fifty percent infectious dose (MID50) was determined following intranasal (i.n.) administration of a small volume (10 μl) of virus suspension. Viruses for use in CTL assays were prepared as described previously by us [18–20].
An influenza NP plasmid DNA vaccine was obtained from Drs. Margaret Liu and Donna Montgomery of Merck Research Laboratories, West Pont, PA [21, 22]. The expression vector system (VIJ) consists of a pUC19 backbone with an IE1 enhancer promoter intron A of hCMV (CMVintA) and a bovine growth hormone (BGH) polyadenylation (poly A) signal sequence for driving the expression of the reporter gene chloramphenicol acetyltransferase (CAT) or the influenza protein . The NP gene from influenza A/PR/8/34 was cloned into the BglII and SalI sites. Plasmid DNA used for vaccination was purified from E. coli (DH5a) containing VIJ-NP by a modified alkaline lysis procedure using QIAGEN (Chatsworth, CA) Giga Plasmid Purification kits. The DNA was banded twice on CsCl2 gradients.
Vaccinia viral gene recombinants
Thymidine kinase-negative (TK-) recombinant vaccinia virus expressing influenza A/PR/8/34 NP gene (NP-Vac) was provided by Dr. Bernard Moss, NIH, Bethesda, MD . Vaccinia recombinant expressing HIV gp120 (Vac-gp120) [24, 25] was obtained from the AIDS Research and Reference Reagents Program, Division of AIDS, NIAID, NIH.
Mice were infected with live virus by administering 0.05 LD50 A/Taiwan/86 by small particle aerosolization [19, 18, 20]. For DNA vaccination, mice were anesthetized by subcutaneous injection of 25 μl of ketamine-xylazine-acepromazine cocktail (37.5/1.9/0.37 mg/ml). The legs of the mice were then flooded with 70% ethanol and NP DNA (200 μg) was injected into each anterior tibial muscle 3 times, 2 weeks apart. Three weeks after the last dose, DNA-immunized mice were challenged with 1 LD50 of A/HK/68 (H3N2) virus by small particle aerosol. Sixty to eighty percent of the mice survived.
Generation of secondary CTL activity and chromium release assay for CTL
Spleen cells were obtained from mice immunized with A/Taiwan/86 and from DNA-immunized mice surviving A/HK/68 virus challenge (after 3–4 months). Influenza virus-specific and NP-specific CTL were generated as previously described [20, 26]. Briefly, stimulator cells were prepared by infecting spleen cells with A/HK/68 (H3N2) virus and washing. In addition, cells were infected with 1 pfu of Vac-NP or Vac-gp120 for 2 hours and irradiated using a cesium source (2500 rads). The stimulators were then co-cultured with responder cells at a 1:10 ratio for 5 days. CTL effectors were harvested, depleted of dead cells using Ficoll Hypaque gradient centrifugation. Tests for CTL activity against A/HK/68-infected P815 (H-2d) target cells was assessed in a 4-hour 51Cr release assay [20, 26].
Purification of CD8+ T cells
CD8+ T cells were purified by negative selection using the magnetic affinity cell sorting MACS method [20, 26, 27]. Alternatively cells were purified by positive selection using AutoMacs mini cell sorter (Miltenyi Biotec, Auburn, CA). Briefly, effector cells (107) were incubated with 20 μl of magnetic CD8a (Ly-2) MicroBeads™ (Miltenyi Biotec; MicroBeads conjugated to rat monoclonal anti-mouse CD8a Ly-2 antibody) for 30 minutes at 4°C and washed. After passing through a column placed in the magnetic field of an AutoMacs, purified CD8+ T cells and CD8- cells (CD4+ T cells, B cells and macrophages) were eluted. The frequency of CD8+ and CD4+ cells in each fraction was determined using PE-conjugated rat anti-mouse CD8a (Ly-2) (clone 53-6.7) and FITC-conjugated Rat Anti-Mouse CD4 (L3T4), IgG2b, clone GK1.5, BD Biosciences) by dual color flow cytometry (Beckman Coulter, Miami, FL). The AutoMacs positive selection is more sensitive than the MACS technique, but the purity of target cells are similar.
Adoptive transfer of T lymphocytes and virus challenge
Purified CD8+ T cells and CD8- cells were suspended in PBS at 1 × 107 cells/ml. Using a 27 gauge needle, naïve mice were injected in the tail vein or intraperitoneally with a 0.1 ml volume to deliver 1 × 107 cells. Four hours later, they were challenged by intranasal inoculation with 10 μl containing 100–200 MID50 of A/HK/68 (H3N2) virus. Lung and nasopharyngeal virus titers were assessed 8 days later.
Quantitation of lung and nasopharyngeal virus
Lungs from infected mice were obtained aseptically at different times following virus challenge and homogenized in vials containing 1 μm glass beads using a Mini-bead beater (Biospec Products, Bartlesville, OK) as previously described [26–28]. For nose washes, jaws of the dead animals were disarticulated and then removed. One ml of 2% FCS-MEM was pushed through each nostril and the effluent collected from the posterior opening of the pallet. Nasal turbinates were also isolated and homogenized as for lungs. Lung, nasal wash and turbinate specimens were titrated for influenza virus in microplates of MDCK tissue cultures [29, 28, 26].
The Mann Whitney nonparametric analysis was used to compare geometric mean titers in different groups. Lung and nasal turbinate homogenates and nose wash samples with undetectable virus titers (< 1 TCID50) were assigned a value of 0.7 TCID10 for statistical evaluation. These tests were performed using STATVIEW Software (SAS Institute, Inc, Cary, NC). A difference between comparison groups of p < 0.05 level was considered significant.
Characterization of purified CD8+ T cells
Specificity of purified CD8+ CTL a
% specific lysis b
% CD8+ cells
% CD4+ cells
Protective effects of NP-specific CD8+
i) T cells from influenza infected mice
ii) T cells from plasmid NP DNA vaccinated mice
The present study was initiated to determine whether CD8+ T cells alone can control an influenza virus infection in the epithelial cells lining the respiratory tract because human influenza virus infection is primarily a mucosal infection with a significant involvement of the upper respiratory tract. In previous reported studies, adoptive transfer of unfractionated influenza immune T cells or cloned influenza-specific CD8+ T cells [4, 31, 1], resulted in significant clearance of influenza virus from the lungs and protection against pneumonia-induced death among the recipient mice. Although, depletion of T cell subsets in vivo suggested that CD8+ T cells were required for clearance of the lung influenza virus infection [5, 6], CD8+ deficient mice results were inconsistent [32, 33, 7]. This was due possibly to unpredictable compensatory mechanisms in these gene knock out animals [34–36]. Although above studies demonstrated or suggested a role for CD8+ cells in the mouse pneumonia model of influenza, they did not evaluate whether they functioned in clearance of influenza virus from the respiratory mucosa.
In the present study, highly purified NP-specific CD8+ CTL, were shown to mediate clearance of influenza infection from both the lung and nasal mucosa of influenza-infected mice. The NP-specific CD8+ CTL were generated from mice immunized with plasmid NP DNA vaccine that survived influenza A virus challenge and from mice immunized with live influenza virus infection by stimulation in vitro with a vaccinia-NP vector. Control CD8+ T cells stimulated with vaccinia-gp120 did not kill influenza virus-infected target cells in vitro and did not mediate clearance of virus in vivo. In addition CD8- cells (including CD4+ T cells, B cells and macrophages) did not mediate clearance of virus. Thus, the present adoptive transfer experiments demonstrate that NP-induced CD8+ CTL can promote clearance of influenza virus infection in epithelial cells lining the respiratory tract. Moreover, we found no evidence for a direct role for CD4+ T cells in viral clearance although they may be important in supporting the development of CD8+ effector T cells [37, 38, 6]. Data from some laboratories have indicated that CD4+ T cells are not required either for the induction or function of CD8+ CTL  while other studies suggest otherwise [38, 6].
Two studies concluded that NP specific T cells do not exhibit antiviral activity in vivo [39, 32]. In one study, mice immunized with influenza NP-vaccinia and challenged with heterotypic influenza A virus had significantly reduced lung virus titers when the mice were challenged 9 and 30 days following immunization but the authors concluded that NP-induced CTLs did not protect against influenza virus challenge . In the second study, mice were immunized with vaccinia constructs expressing NP147–155 epitopic peptide and then challenged 9 days later with a lethal dose of heterotypic influenza A virus . These NP peptide vaccinia constructs failed to reduce lung virus titers and mortality but the CTLs were directed to a single NP epitope and were probably inadequate to protect against a lethal influenza challenge.
The role of contact-mediated T cell cytotoxicity against cytopathic viruses such as influenza remains controversial. Some studies have suggested that cytokines released by T cells and neutralizing antibodies constitute the primary protective mechanisms . In a study by Doherty's group, it was shown that mice primed with influenza A/H1N1 virus clear an A/H3N2 influenza challenge 2–3 days earlier than naïve mice . It was further shown that virus-specific CD8+ T cells produce IFN-γ within six hours while it takes 4–5 days for CD8+ T cells to accumulate in the infected local mucosal epithelium . In those studies, the kinetics of reduction in lung virus titer preceded the accumulation of virus-specific NP366–474tetramer+ CD8+ T cells, but reductions partially overlapped peak accumulation of the CD8+ T cells. Other studies using perforin and Fas deficient chimeric mice (P-/-/Fas-/-) showed that CD8+ CTL could clear influenza virus infection via a perforin-dependent pathway and, in the absence of perforin, via virus-infected lung cells expressing Fas . These results are indicative of a contact-dependent mechanism requiring perforin and/or Fas. The results presented here represent a direct demonstration that CD8+ T cells constitute an effective mechanism for clearance of influenza virus infection in the upper respiratory mucosa. Thus, the suggestion that antigen-specific CTLs cannot cross the basement membrane to function effectively on infected epithelial cells does not appear to be true .
These results support an effector role for CD8+ CTL activity in the results of McMichael and coworkers who showed an inverse correlation between influenza virus shedding from the nose and the level of HLA-restricted CD8+ CTL activity in the blood of human volunteers challenged with an influenza virus . In this regard, it is important to emphasize that the function of CD8+ CTL is not to prevent viral infection but rather to mediate clearance of an infection and, thereby, promote recovery from disease and a reduction in disease severity . Currently available data indicate that prevention of influenza infection requires induction of antibody to the surface viral hemagglutinin (HA) or the NA in both serum and respiratory secretions . An obvious implication of the present findings is that NP-specific CD8+ CTL activity can augment protection against influenza induced by antibody and is a desirable immune response for influenza vaccines.
This work was funded in part by US Public Health Service NIAID, NIH (Respiratory Pathogens Research Unit; NO1-A1-65298) and RO1-AG10057. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
The authors thank Catherine L. Acuna, Kirsten C. Switzer, Ying Wang and Xyanthine Gilmore for excellent technical assistance.
- Yap KL, Braciale TJ, Ada GL: Role of T-cell function in recovery from murine influenza infection. Cell Immunol 1979,43(2):341–351.View ArticlePubMedGoogle Scholar
- Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, Stevenson PG: Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997, 159:105–117.View ArticlePubMedGoogle Scholar
- Lukacher AE, Braciale VL, Braciale TJ: In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 1984,160(3):814–826.View ArticlePubMedGoogle Scholar
- Yap KL, Ada GL, McKenzie IF: Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978,273(5659):238–239.View ArticlePubMedGoogle Scholar
- Lightman S, Cobbold S, Waldmann H, Askonas BA: Do L3T4+ T cells act as effector cells in protection against influenza virus infection. Immunology 1987,62(1):139–144.PubMedPubMed CentralGoogle Scholar
- Topham DJ, Doherty PC: Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells. J Virol 1998,72(1):882–885.PubMedPubMed CentralGoogle Scholar
- Bender BS, Croghan T, Zhang L, Small PA Jr.: Transgenic mice lacking class I major histocompatibility complex- restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 1992,175(4):1143–1145.View ArticlePubMedGoogle Scholar
- Treanor JJ: Influenza virus. In Principles and Practice of Infectious Diseases. 6th edition. Edited by: Mandell Gerad L. BJEDR. Philadelphia , Elsever, Inc.; 2005:2060–2085.Google Scholar
- Kagi D, Hengartner H: Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr Opin Immunol 1996,8(4):472–477.View ArticlePubMedGoogle Scholar
- McMichael AJ, Gotch FM, Noble GR, Beare PA: Cytotoxic T-cell immunity to influenza. N Engl J Med 1983,309(1):13–17.View ArticlePubMedGoogle Scholar
- Gotch F, McMichael A, Smith G, Moss B: Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 1987,165(2):408–416.View ArticlePubMedGoogle Scholar
- McMichael AJ, Michie CA, Gotch FM, Smith GL, Moss B: Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 1986,67(Pt 4):719–726.View ArticlePubMedGoogle Scholar
- Townsend A, Bastin J, Bodmer H, Brownlee G, Davey J, Gotch F, Gould K, Jones I, McMichael A, Rothbard J, et al.: Recognition of influenza virus proteins by cytotoxic T lymphocytes. Philos Trans R Soc Lond B Biol Sci 1989,323(1217):527–533.View ArticlePubMedGoogle Scholar
- Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ: The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986,44(6):959–968.View ArticlePubMedGoogle Scholar
- Virelizier JL, Oxford JS, Schild GC: The role of humoral immunity in host defence against influenza A infection in mice. Postgrad Med J 1976,52(608):332–337.View ArticlePubMedPubMed CentralGoogle Scholar
- Virelizier JL: Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J Immunol 1975,115(2):434–439.PubMedGoogle Scholar
- Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR: Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990,64(3):1375–1377.PubMedPubMed CentralGoogle Scholar
- Mbawuike IN, Wyde PR, Anderson PM: Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine 1990,8(4):347–352.View ArticlePubMedGoogle Scholar
- Mbawuike IN, Six HR, Cate TR, Couch RB: Vaccination with inactivated influenza A virus during pregnancy protects neonatal mice against lethal challenge by influenza A viruses representing three subtypes. J Virol 1990,64(3):1370–1374.PubMedPubMed CentralGoogle Scholar
- Mbawuike IN J Galarza, DF Summers and RB Couch: A baculovirus-expressed influenza A/Udorn (H3N2) nucleoprotein induces protective T Cell immunity against influenza A/H3N2 and A/H1N1 in mice. Vaccine Research 1994, 3:211–227.Google Scholar
- Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, Donnelly JJ, Liu MA: Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 1993,12(9):777–783.View ArticlePubMedGoogle Scholar
- Ulmer JB, Deck RR, DeWitt CM, Friedman A, Donnelly JJ, Liu MA: Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 1994,12(16):1541–1544.View ArticlePubMedGoogle Scholar
- Yewdell JW, Bennink JR, Smith GL, Moss B: Influenza A virus nucleoprotein is a major target antigen for cross- reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1985,82(6):1785–1789.View ArticlePubMedPubMed CentralGoogle Scholar
- Earl PL, Hugin AW, Moss B: Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J Virol 1990,64(5):2448–2451.PubMedPubMed CentralGoogle Scholar
- Earl PL, Koenig S, Moss B: Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J Virol 1991,65(1):31–41.PubMedPubMed CentralGoogle Scholar
- Mbawuike IN, Dillon SB, Demuth SG, Jones CS, Cate TR, Couch RB: Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein. Vaccine 1994,12(14):1340–1348.View ArticlePubMedGoogle Scholar
- Mbawuike IN, Acuna C, Caballero D, Pham-Nguyen K, Gilbert B, Petribon P, Harmon M: Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Cell Immunol 1996,173(1):64–78.View ArticlePubMedGoogle Scholar
- Mbawuike IN, Wyde PR: Induction of CD8+ cytotoxic T cells by immunization with killed influenza virus and effect of cholera toxin B subunit. Vaccine 1993,11(12):1205–1213.View ArticlePubMedGoogle Scholar
- Baxter BD, Couch RB, Greenberg SB, Kasel JA: Maintenance of viability and comparison of identification methods for influenza and other respiratory viruses of humans. J Clin Microbiol 1977,6(1):19–22.PubMedPubMed CentralGoogle Scholar
- Yetter RA, Lehrer S, Ramphal R, Small PA Jr.: Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun 1980,29(2):654–662.PubMedPubMed CentralGoogle Scholar
- Yap KL, Ada GL: The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen. Scand J Immunol 1978,8(5):413–420.View ArticlePubMedGoogle Scholar
- Epstein SL, Misplon JA, Lawson CM, Subbarao EK, Connors M, Murphy BR: Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J Immunol 1993,150(12):5484–5493.PubMedGoogle Scholar
- Bender BS, Bell WE, Taylor S, Small PA Jr.: Class I major histocompatibility complex-restricted cytotoxic T lymphocytes are not necessary for heterotypic immunity to influenza. J Infect Dis 1994,170(5):1195–1200.View ArticlePubMedGoogle Scholar
- Eichelberger M, Allan W, Zijlstra M, Jaenisch R, Doherty PC: Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med 1991,174(4):875–880.View ArticlePubMedGoogle Scholar
- Hou S, Doherty PC, Zijlstra M, Jaenisch R, Katz JM: Delayed clearance of Sendai virus in mice lacking class I MHC- restricted CD8+ T cells. J Immunol 1992,149(4):1319–1325.PubMedGoogle Scholar
- Doherty PC: Virus infections in mice with targeted gene disruptions. Curr Opin Immunol 1993,5(4):479–483.View ArticlePubMedGoogle Scholar
- Allan W, Tabi Z, Cleary A, Doherty PC: Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. J Immunol 1990,144(10):3980–3986.PubMedGoogle Scholar
- Topham DJ, Tripp RA, Sarawar SR, Sangster MY, Doherty PC: Immune CD4+ T cells promote the clearance of influenza virus from major histocompatibility complex class II -/- respiratory epithelium. J Virol 1996,70(2):1288–1291.PubMedPubMed CentralGoogle Scholar
- Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR: Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol 1994,68(6):3505–3511.PubMedPubMed CentralGoogle Scholar
- Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC: Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998,8(6):683–691.View ArticlePubMedGoogle Scholar
- Topham DJ, Tripp RA, Doherty PC: CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 1997,159(11):5197–5200.PubMedGoogle Scholar
- McMichael A: Cytotoxic T lymphocytes: specificity, surveillance, and escape. Adv Cancer Res 1992, 59:227–244.View ArticlePubMedGoogle Scholar
- Couch RB, Kasel JA: Immunity to influenza in man. Annu Rev Microbiol 1983, 37:529–549.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.